RightFit Trial Directory

Lung Cancer clinical trials in San Francisco, CA

23 recruiting lung cancer studies with a site in San Francisco, CA.

All trials in San Francisco, CA · All Lung Cancer trials

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Anaheim, CA · Antioch, CA · Arroyo Grande, CA · +1147 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Duarte, CA · Irvine, CA · Los Angeles, CA · +26 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Beverly Hills, CA · Dublin, CA · Fremont, CA · +278 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Fullerton, CA · Long Beach, CA · Los Angeles, CA · +51 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

Irvine, CA · Los Angeles, CA · San Francisco, CA · +12 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Los Angeles, CA · San Francisco, CA · +18 more sites

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Anaheim, CA · Auburn, CA · Baldwin Park, CA · +275 more sites

RecruitingPhase 1 / Phase 2NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor: BioNTech SE

San Francisco, CA · +18 more sites

RecruitingPhase 2NCT07492680

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor: Bristol-Myers Squibb

San Francisco, CA · +15 more sites

RecruitingPhase 1NCT07164313

A Study of ZW251 in Participants With Advanced Solid Tumors

Sponsor: Zymeworks BC Inc.

San Francisco, CA · Santa Monica, CA · +6 more sites

RecruitingNot applicableNCT07059884

Distance-Based Exercise to Preserve Function and Prevent Disability

Sponsor: Alliance for Clinical Trials in Oncology

Dublin, CA · Fremont, CA · Fresno, CA · +20 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Los Angeles, CA · Sacramento, CA · San Francisco, CA · +53 more sites

RecruitingPhase 1NCT07080242

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Sponsor: SystImmune Inc.

Glendale, CA · Long Beach, CA · Los Angeles, CA · +21 more sites

RecruitingPhase 1NCT07217171

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Sponsor: EvolveImmune United, Inc

Duarte, CA · Los Angeles, CA · San Francisco, CA · +13 more sites

RecruitingPhase 1 / Phase 2NCT07491497

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Sponsor: TRIANA Biomedicines, Inc.

San Francisco, CA · +13 more sites

RecruitingPhase 1 / Phase 2NCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Sponsor: Merck Sharp & Dohme LLC

Duarte, CA · San Francisco, CA · +16 more sites

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Fullerton, CA · Los Angeles, CA · San Francisco, CA · +27 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Anaheim, CA · Arroyo Grande, CA · +451 more sites

RecruitingPhase 1NCT06917079

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Los Angeles, CA · Sacramento, CA · San Diego, CA · +13 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Anaheim, CA · Antioch, CA · Arroyo Grande, CA · +1226 more sites

RecruitingPhase 1 / Phase 2NCT06244771

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Sponsor: Frontier Medicines Corporation

La Jolla, CA · Orange, CA · San Francisco, CA · +12 more sites

RecruitingPhase 2NCT04079179

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Sponsor: Carl Allen

Orange, CA · San Francisco, CA · +10 more sites

RecruitingPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

Sponsor: Nurix Therapeutics, Inc.

Duarte, CA · Los Angeles, CA · San Francisco, CA · +7 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.